Aktiesnakken — September 2013
-
det er fornuftigt. Meget
-
fedt solsen
-
du har fortjent det
-
Det er yderst fortjent..
-
Genmab CEO: Moralen er skyhøj: http://medwatch.dk/secure/Medicinal___Biotek/article5958184.ece
-
i fredags talte jeg toppen i GSK, og de er også yderst begejstrede
-
Det giver mulighed for en rigtig god label siger han
-
Jan kan nærmest ikke får armene ned for tiden. Virker som om han hele tiden har mere i godteposen som han ikke siger

-
Jeps
han siger det selv: Bredere label, hurtigere godkendelse, lægerne tager bedre imod stoffet etc.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind